Episode Summary
Executive Summary: Peter Atiyah interviews psychopharmacologist Celia Morgan about ketamine’s biology, history, risks, and emerging psychiatric uses. They contrast ketamine with classic psychedelics, explain its NMDA/glutamate mechanisms, and focus on evidence for treatment-resistant depression and alcohol use disorder. A major theme is that ketamine appears most useful when paired with psychotherapy, not as a stand-alone or indefinite maintenance drug.
Main Topics: Ketamine’s pharmacology and neurobiology (Priority: 5/5): Morgan explains ketamine as a dissociative anesthetic acting primarily on NMDA receptors, affecting glutamate and GABA circuits, with dose-dependent effects ranging from mild intoxication to anesthesia and dissociation. Medical history and anesthetic utility (Priority: 4/5): The discussion covers ketamine’s origin as a PCP analog, its development as an anesthetic, why it remains widely used in trauma, pediatrics, battlefield medicine, and settings where respiratory depression is dangerous. Risks, abuse potential, and toxicity (Priority: 5/5): They discuss recreational use, dependence, bladder toxicity, accidents during dissociation, and why ketamine’s safety profile is not equivalent to harmlessness despite low respiratory risk. Ketamine for treatment-resistant depression (Priority: 5/5): Morgan reviews the Yale-originated depression studies showing rapid antidepressant effects, the variability of response, the short duration of benefit, and the need to identify who benefits and for how long. Ketamine plus psychotherapy as a treatment model (Priority: 5/5): A central argument is that ketamine may work best as a catalyst for therapy during a window of increased plasticity, rather than as a repeated standalone medication or long-term maintenance drug. Ketamine in alcohol and addiction treatment (Priority: 4/5): Morgan describes trials in alcohol use disorder showing strong abstinence outcomes when ketamine is combined with structured therapy, and discusses similar promise in other addictions. Clinical practice, regulation, and ketamine clinics (Priority: 4/5): The conversation critiques the rapid expansion of ketamine clinics, the lack of registries and long-term data, and the concern that commercial incentives may outpace evidence-based use.
Key Arguments: Ketamine is pharmacologically distinct from LSD and psilocybin because it primarily acts on NMDA/glutamate systems rather than 5-HT2A serotonin receptors. Its anesthetic value comes from preserving respiration and often blood pressure, making it especially useful in trauma, pediatrics, and low-resource settings. Recreational high-dose ketamine can be dangerous because dissociation impairs judgment and awareness, leading to accidents and direct organ toxicity, especially bladder damage. The antidepressant effect can be rapid in treatment-resistant depression, but response is variable and often short-lived, so repeated dosing or maintenance may be needed for some patients. The acute dissociative experience may not be a nuisance side effect only; more nuanced features of the experience may predict therapeutic benefit better than crude dissociation scales. Psychological therapy likely matters because ketamine may increase synaptic plasticity, creating a window in which patients can learn new patterns and behaviors. In alcohol use disorder, ketamine combined with therapy produced stronger abstinence outcomes than ketamine or education alone, suggesting synergy rather than drug-only efficacy. Commercial ketamine clinics may be overextending the drug beyond the evidence base, especially if they offer frequent or unsupervised dosing without psychotherapy. Long-term daily or twice-weekly ketamine use raises concerns about tolerance, dose escalation, and cumulative harm, even if acute respiratory toxicity is low.
Data Points: Ketamine dose for depression studies: 0.5 mg/kg IV over 40 minutes - Early Yale depression trials and acute research studies Higher dose used in alcohol trial: 0.8 mg/kg - Morgan’s alcohol-use-disorder trial with psychotherapy Recreational dose estimate: 100-200 mg - Typical high recreational dose discussed as much larger than clinical dosing Response rate in treatment-resistant depression: about 50-60% - Morgan’s estimate of clinical-trial response rates over time Duration of antidepressant benefit: about 2 days to 1 week, sometimes up to 2 weeks - Typical length of benefit after ketamine infusion Dependence/craving in recreational users: 9% - Study of non-medical ketamine users Alcohol trial abstinence at 6 months: 86% - Ketamine plus therapy arm in Morgan’s four-arm study Alcohol trial abstinence in control/education arm: 68% - Education-only / non-ketamine arm still showed substantial improvement Alcohol trial sample size: 96 patients total - Four-arm study with 24 patients per arm Planned phase 3 alcohol trial size: 280 patients - NHS-funded follow-up efficacy study Therapy exposure in alcohol trial: about 11 hours total - Manualized psychotherapy delivered around ketamine sessions Ketamine session count in alcohol trial: 3 infusions - Given with therapy and spaced about a week to two weeks apart Peak synaptic plasticity window: starts around 4 hours, peaks around 24 hours - Animal data used to time psychotherapy after ketamine Blood pressure threshold mentioned: above 180 systolic - One infusion was stopped when blood pressure rose too high Ketamine clinic maintenance schedule (Spravato): twice weekly for a month, then weekly - Discussed as labeled intranasal ketamine regimen
Pivotal Quotes: "the dose kind of makes the poison" — Celia Morgan: Explaining ketamine’s wide range of effects from mild dissociation to anesthesia and danger "If you just do the ketamine, you should certainly try it embedded within therapy." — Celia Morgan: Her core recommendation for clinical use in depression and addiction "we saw the strongest or greatest reductions in drinking and greatest abstinence in ketamine and therapy group" — Celia Morgan: Summarizing the alcohol-use-disorder trial results
Implications: Ketamine is promising but should be used cautiously, ideally with psychotherapy and careful screening. The biggest opportunity is targeted, time-limited treatment for resistant depression and addiction—not open-ended clinic-based dosing without strong evidence.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.